YD Bio

YD Bio Enterprise Value

The Enterprise Value (EV) of YD Bio (YDES) as of Oct 17, 2026 is 508.81 M USD. In the previous year, Enterprise Value (EV) was 511.70 M USD — a change of -0.57% (lower).

Enterprise Value

508.81 MUSD

YoY

-0.57%

Last updated:

Enterprise Value (EV) of YD Bio is 2025 508.81 M USD. Enterprise Value (EV) of YD Bio was 2024 511.70 M USD. It decreases by -0.57% lower compared to the previous year.

The YD Bio Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2020
514.12 M USD
Jan 1, 2021
514.80 M USD
Jan 1, 2022
514.80 M USD
Jan 1, 2023
514.77 M USD
Jan 1, 2024
511.70 M USD
Jan 1, 2025
508.81 M USD
The YD Bio Enterprise Value history
YEAREnterprise ValueYoY
508.81 MUSD-0.57%
511.70 MUSD-0.60%
514.77 MUSD-0.00%
514.80 MUSD-0.00%
514.80 MUSD+0.13%
514.12 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

YD Bio Stock analysis

What does YD Bio do? YD Bio Ltd is a company based in Taipei City, Taiwan, with its headquarters located in Taipei City. The company is set to go public on August 29, 2025, under the ticker symbol YDES and ISIN KYG983011076. YD Bio Ltd focuses on developing innovative solutions in the healthcare sector, particularly in early cancer detection and next-generation cell therapies. The company's core activities include creating non-invasive cancer detection tools for early diagnosis and monitoring, as well as developing ophthalmologic products for dry eye conditions. Additionally, YD Bio Ltd is engaged in exosome-based therapeutics designed to address complex diseases. The company aims to enhance patient outcomes and quality of life through the integration of advanced scientific research with practical, accessible healthcare solutions. YD Bio Ltd operates within the healthcare industry, though specific sector and industry classifications are not provided. The company's website is http://ir.ydesgroup.com/, where further information about its operations and future plans can be found. As a Taiwan-based entity, YD Bio Ltd contributes to the biotechnology and medical innovation landscape in the region. The company's IPO date is scheduled for 2025, indicating its readiness to expand its market presence and potentially scale its operations. YD Bio Ltd's mission centers on pioneering transformative healthcare solutions that improve and extend patient lives. YD Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about YD Bio stock

Enterprise Value (EV) of YD Bio is 508.81 M USD in 2025.

Enterprise Value (EV) of YD Bio changed from 511.70 M USD to 508.81 M USD, representing a -0.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) YD Bio since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s YD Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — YD Bio

All Key Metrics — YD Bio